Menarini Group Completes Acquisition of Stemline Therapeutics

Menarini Group today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash consideration up to $677 million on a fully diluted basis.

Menarini Invests 150 Million Euros in a New Pharmaceutical Plant in Italy

Menarini chooses Italy for its new €150 million manufacturing site.

Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

Menarini Group and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreement under which Menarini Group will acquire Stemline in a transaction valued up to $677 million.

Menarini: Elcin Barker Ergun Group CEO

The Board of Directors has appointed Mrs. Elcin Barker Ergun as CEO of Menarini Group

Menarini's evening with the stars of Fair Play

The 23rd Menarini International Fair Play Awards will take place in Florence. An evening dedicated...

123

Οι αξίες μας

10 βασικές αξίες έχουν επηρεάσει την πρόοδο της ομάδας μας

Diagnostics

Προχωρημένη τεχνολογία

Άριστη Ποιότητα

Ποιότητα: Σημείο αναφοράς για τα φάρμακα μας

Menarini στον κόσμο

Ο Όμιλος Menarini έχει εταιρείες που βρίσκονται σχεδόν σε όλο τον κόσμο
Scorri in alto